Larimar Therapeutics, Inc. (LRMR)
- Previous Close
6.46 - Open
6.48 - Bid 6.42 x 100
- Ask 6.49 x 300
- Day's Range
6.32 - 6.50 - 52 Week Range
2.18 - 13.68 - Volume
219,360 - Avg. Volume
651,109 - Market Cap (intraday)
412.148M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.84 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.40
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
www.larimartx.comRecent News: LRMR
Performance Overview: LRMR
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LRMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LRMR
Valuation Measures
Market Cap
412.15M
Enterprise Value
330.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-7.98
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.48%
Return on Equity (ttm)
-38.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.95M
Diluted EPS (ttm)
-0.84
Balance Sheet and Cash Flow
Total Cash (mrq)
86.79M
Total Debt/Equity (mrq)
6.79%
Levered Free Cash Flow (ttm)
-20.84M